Earnings Call Insights: Johnson & Johnson (JNJ) Q1 2025
Management View
- CEO Joaquin Duato highlighted strong operational sales growth of 4.2% with contributions from both Innovative Medicine and MedTech segments. He emphasized the company’s resilience despite the loss of exclusivity for STELARA, attributing